{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T19:43:50Z","timestamp":1790883830311,"version":"4.1.0"},"reference-count":198,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T00:00:00Z","timestamp":1761696000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T00:00:00Z","timestamp":1761696000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01-CA282901"],"award-info":[{"award-number":["R01-CA282901"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011566","name":"Sidney Kimmel Comprehensive Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011566","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Department of Pharmacology and Physiology, Drexel University"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Metastasis Rev"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Uveal melanoma (UM) is an aggressive intraocular malignancy in adults arising from the melanocytes of the uveal tract. While primary UM lesions can be successfully treated,\u2009~\u200950% of UM patients develop metastases primarily in the liver. Patients with liver metastatic UM (LMUM) have poor prognosis and few therapeutic options. LMUM lesions are unresponsive to standard chemotherapies, targeted therapies, and immune checkpoint inhibitors \u2014 an effect at least in part associated with the detoxification function of the liver and the diverse hepatic immunological landscape. Here, we recount the etiology and molecular mechanisms in the development of LMUM, examine the influences of the hepatic tumor microenvironment (TME) on UM liver tropism, and review how the innate and peripheral immune response contributes to LMUM progression and therapeutic efficacy. The unique immunological properties of the liver coupled with the distinct growth patterns of LMUM lesions present significant challenges for developing effective treatments that can overcome this specialized microenvironment. Improved understanding of the interplay between the liver and LMUM is essential for the development of more effective diagnostic techniques and improved therapeutic outcomes.<\/jats:p>","DOI":"10.1007\/s10555-025-10298-8","type":"journal-article","created":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T15:31:31Z","timestamp":1761751891000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Functions and clinical implications of the liver microenvironment in hepatic uveal melanoma metastases"],"prefix":"10.1007","volume":"44","author":[{"given":"Camille J.","family":"Cunanan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alyssa B.","family":"Sanders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayla C.","family":"Gallant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rino S.","family":"Seedor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward J.","family":"Hartsough","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,29]]},"reference":[{"issue":"1","key":"10298_CR1","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/s41572-022-00339-9","volume":"8","author":"MJ Jager","year":"2022","unstructured":"Jager, M. J., et al. (2022). Author correction: Uveal melanoma. Nature Reviews Disease Primers, 8(1), 4.","journal-title":"Nature Reviews Disease Primers"},{"issue":"2","key":"10298_CR2","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/eye.2016.275","volume":"31","author":"S Kaliki","year":"2017","unstructured":"Kaliki, S., & Shields, C. L. (2017). Uveal melanoma: Relatively rare but deadly cancer. Eye, 31(2), 241\u2013257.","journal-title":"Eye"},{"issue":"5","key":"10298_CR3","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1002\/cncr.20866","volume":"103","author":"CC McLaughlin","year":"2005","unstructured":"McLaughlin, C. C., et al. (2005). Incidence of noncutaneous melanomas in the U.S. Cancer, 103(5), 1000\u20131007.","journal-title":"Cancer"},{"issue":"2","key":"10298_CR4","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/s41571-022-00714-1","volume":"20","author":"RD Carvajal","year":"2023","unstructured":"Carvajal, R. D., et al. (2023). Advances in the clinical management of uveal melanoma. Nature Reviews Clinical Oncology, 20(2), 99\u2013115.","journal-title":"Nature Reviews Clinical Oncology"},{"issue":"4","key":"10298_CR5","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.aopr.2024.10.001","volume":"4","author":"X Hou","year":"2024","unstructured":"Hou, X., et al. (2024). Global incidence and prevalence in uveal melanoma. Advances in Ophthalmology Practice and Research, 4(4), 226\u2013232.","journal-title":"Advances in Ophthalmology Practice and Research"},{"issue":"4","key":"10298_CR6","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1016\/j.ajo.2005.05.034","volume":"140","author":"DN Hu","year":"2005","unstructured":"Hu, D. N., et al. (2005). Population-based incidence of uveal melanoma in various races and ethnic groups. American Journal of Ophthalmology, 140(4), 612\u2013617.","journal-title":"American Journal of Ophthalmology"},{"issue":"8","key":"10298_CR7","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1016\/j.ophtha.2012.01.048","volume":"119","author":"EM Damato","year":"2012","unstructured":"Damato, E. M., & Damato, B. E. (2012). Detection and time to treatment of uveal melanoma in the United Kingdom: An evaluation of 2,384 patients. Ophthalmology, 119(8), 1582\u20131589.","journal-title":"Ophthalmology"},{"issue":"5","key":"10298_CR8","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1016\/j.ajhg.2016.09.008","volume":"99","author":"B Royer-Bertrand","year":"2016","unstructured":"Royer-Bertrand, B., et al. (2016). Comprehensive genetic landscape of uveal melanoma by whole-genome sequencing. American Journal of Human Genetics, 99(5), 1190\u20131198.","journal-title":"American Journal of Human Genetics"},{"issue":"12","key":"10298_CR9","doi-asserted-by":"publisher","first-page":"5230","DOI":"10.1167\/iovs.08-2145","volume":"49","author":"MD Onken","year":"2008","unstructured":"Onken, M. D., et al. (2008). Oncogenic mutations in GNAQ occur early in uveal melanoma. Investigative Ophthalmology & Visual Science, 49(12), 5230\u20135234.","journal-title":"Investigative Ophthalmology & Visual Science"},{"key":"10298_CR10","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13215503","author":"RS Seedor","year":"2021","unstructured":"Seedor, R. S., Orloff, M., & Sato, T. (2021). Genetic landscape and emerging therapies in uveal melanoma. Cancers. https:\/\/doi.org\/10.3390\/cancers13215503","journal-title":"Cancers"},{"issue":"23","key":"10298_CR11","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1056\/NEJMoa1000584","volume":"363","author":"CD Van Raamsdonk","year":"2010","unstructured":"Van Raamsdonk, C. D., et al. (2010). Mutations in GNA11 in uveal melanoma. New England Journal of Medicine, 363(23), 2191\u20132199.","journal-title":"New England Journal of Medicine"},{"issue":"11","key":"10298_CR12","doi-asserted-by":"publisher","first-page":"4651","DOI":"10.1167\/iovs.03-0538","volume":"44","author":"E Kujala","year":"2003","unstructured":"Kujala, E., Makitie, T., & Kivela, T. (2003). Very long-term prognosis of patients with malignant uveal melanoma. Investigative Ophthalmology & Visual Science, 44(11), 4651\u20134659.","journal-title":"Investigative Ophthalmology & Visual Science"},{"issue":"5","key":"10298_CR13","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1001\/archopht.119.5.670","volume":"119","author":"Collaborative Ocular Melanoma Study, G.","year":"2001","unstructured":"Collaborative Ocular Melanoma Study, G. (2001). Assessment of metastatic disease status at death in 435 patients with large choroidal melanoma in the Collaborative Ocular Melanoma Study (COMS): COMS report. 15. Archives of Ophthalmology, 119(5), 670\u20136.","journal-title":"Archives of Ophthalmology"},{"issue":"10","key":"10298_CR14","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1016\/j.ophtha.2019.04.027","volume":"126","author":"P Vichitvejpaisal","year":"2019","unstructured":"Vichitvejpaisal, P., et al. (2019). Genetic analysis of uveal melanoma in 658 patients using the Cancer Genome Atlas Classification of Uveal Melanoma as A, B, C, and D. Ophthalmology, 126(10), 1445\u20131453.","journal-title":"Ophthalmology"},{"issue":"2","key":"10298_CR15","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.ccell.2017.07.003","volume":"32","author":"AG Robertson","year":"2017","unstructured":"Robertson, A. G., et al. (2017). Integrative analysis identifies four molecular and clinical subsets in uveal melanoma. Cancer Cell, 32(2), 204-220.e15.","journal-title":"Cancer Cell"},{"key":"10298_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11081061","author":"MF Bakhoum","year":"2019","unstructured":"Bakhoum, M. F., & Esmaeli, B. (2019). Molecular characteristics of uveal melanoma: Insights from the Cancer Genome Atlas (TCGA) project. Cancers. https:\/\/doi.org\/10.3390\/cancers11081061","journal-title":"Cancers"},{"key":"10298_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13215457","author":"R Tanaka","year":"2021","unstructured":"Tanaka, R., et al. (2021). The role of HGF\/MET signaling in metastatic uveal melanoma. Cancers. https:\/\/doi.org\/10.3390\/cancers13215457","journal-title":"Cancers"},{"issue":"2","key":"10298_CR18","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1097\/CMR.0000000000000807","volume":"32","author":"AM Steckler","year":"2022","unstructured":"Steckler, A. M., et al. (2022). Uveal melanoma metastatic at initial diagnosis: A case series. Melanoma Research, 32(2), 120\u2013123.","journal-title":"Melanoma Research"},{"issue":"21","key":"10298_CR19","doi-asserted-by":"publisher","first-page":"R1147","DOI":"10.1016\/j.cub.2017.09.019","volume":"27","author":"E Trefts","year":"2017","unstructured":"Trefts, E., Gannon, M., & Wasserman, D. H. (2017). The liver. Current Biology, 27(21), R1147\u2013R1151.","journal-title":"Current Biology"},{"issue":"3","key":"10298_CR20","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.jhep.2019.10.003","volume":"72","author":"A Albillos","year":"2020","unstructured":"Albillos, A., de Gottardi, A., & Rescigno, M. (2020). The gut-liver axis in liver disease: Pathophysiological basis for therapy. Journal of Hepatology, 72(3), 558\u2013577.","journal-title":"Journal of Hepatology"},{"issue":"5","key":"10298_CR21","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.cmet.2013.03.013","volume":"17","author":"TQ de Aguiarvallim","year":"2013","unstructured":"de Aguiarvallim, T. Q., Tarling, E. J., & Edwards, P. A. (2013). Pleiotropic roles of bile acids in metabolism. Cell Metabolism, 17(5), 657\u2013669.","journal-title":"Cell Metabolism"},{"issue":"2","key":"10298_CR22","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/S1665-2681(19)31651-5","volume":"9","author":"G Ramadori","year":"2010","unstructured":"Ramadori, G., & Cameron, S. (2010). Effects of systemic chemotherapy on the liver. Annals Of Hepatology, 9(2), 133\u2013143.","journal-title":"Annals Of Hepatology"},{"key":"10298_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/cells13231958","author":"IM Mokhosoev","year":"2024","unstructured":"Mokhosoev, I. M., et al. (2024). Human cytochrome P450 cancer-related metabolic activities and gene polymorphisms: A review. Cells. https:\/\/doi.org\/10.3390\/cells13231958","journal-title":"Cells"},{"key":"10298_CR24","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1016\/j.redox.2017.01.012","volume":"11","author":"T Kietzmann","year":"2017","unstructured":"Kietzmann, T. (2017). Metabolic zonation of the liver: The oxygen gradient revisited. Redox Biology, 11, 622\u2013630.","journal-title":"Redox Biology"},{"issue":"4","key":"10298_CR25","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1002\/hep.32408","volume":"76","author":"J Paris","year":"2022","unstructured":"Paris, J., & Henderson, N. C. (2022). Liver zonation, revisited. Hepatology, 76(4), 1219\u20131230.","journal-title":"Hepatology"},{"key":"10298_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2022.806408","volume":"10","author":"S Yu","year":"2022","unstructured":"Yu, S., et al. (2022). Significance of liver zonation in hepatocellular carcinoma. Frontiers in Cell and Developmental Biology, 10, Article 806408.","journal-title":"Frontiers in Cell and Developmental Biology"},{"key":"10298_CR27","doi-asserted-by":"publisher","first-page":"1083780","DOI":"10.3389\/fimmu.2022.1083780","volume":"13","author":"J Gong","year":"2022","unstructured":"Gong, J., et al. (2022). Hepatocytes: A key role in liver inflammation. Frontiers in Immunology, 13, 1083780.","journal-title":"Frontiers in Immunology"},{"issue":"7","key":"10298_CR28","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1083\/jcb.201903090","volume":"218","author":"RJ Schulze","year":"2019","unstructured":"Schulze, R. J., et al. (2019). The cell biology of the hepatocyte: A membrane trafficking machine. Journal of Cell Biology, 218(7), 2096\u20132112.","journal-title":"Journal of Cell Biology"},{"issue":"7747","key":"10298_CR29","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/s41586-019-1004-y","volume":"567","author":"JW Lee","year":"2019","unstructured":"Lee, J. W., et al. (2019). Hepatocytes direct the formation of a pro-metastatic niche in the liver. Nature, 567(7747), 249\u2013252.","journal-title":"Nature"},{"issue":"12","key":"10298_CR30","doi-asserted-by":"publisher","first-page":"5522","DOI":"10.1167\/iovs.09-3804","volume":"50","author":"H Li","year":"2009","unstructured":"Li, H., et al. (2009). Inhibition of chemokine receptor expression on uveal melanomas by CXCR4 siRNA and its effect on uveal melanoma liver metastases. Investigative Ophthalmology & Visual Science, 50(12), 5522\u20135528.","journal-title":"Investigative Ophthalmology & Visual Science"},{"issue":"9","key":"10298_CR31","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1038\/s41575-018-0020-y","volume":"15","author":"S Shetty","year":"2018","unstructured":"Shetty, S., Lalor, P. F., & Adams, D. H. (2018). Liver sinusoidal endothelial cells - Gatekeepers of hepatic immunity. Nature Reviews Gastroenterology & Hepatology, 15(9), 555\u2013567.","journal-title":"Nature Reviews Gastroenterology & Hepatology"},{"issue":"1","key":"10298_CR32","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-024-05430-1","volume":"22","author":"L Ma","year":"2024","unstructured":"Ma, L., et al. (2024). Senescent endothelial cells promote liver metastasis of uveal melanoma in single-cell resolution. Journal of Translational Medicine, 22(1), Article 605.","journal-title":"Journal of Translational Medicine"},{"key":"10298_CR33","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1146\/annurev-pathol-121808-102144","volume":"5","author":"JP Coppe","year":"2010","unstructured":"Coppe, J. P., et al. (2010). The senescence-associated secretory phenotype: The dark side of tumor suppression. Annual Review of Pathology, 5, 99\u2013118.","journal-title":"Annual Review of Pathology"},{"issue":"8","key":"10298_CR34","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1158\/1541-7786.MCR-21-0657","volume":"20","author":"U Baqai","year":"2022","unstructured":"Baqai, U., et al. (2022). Multi-omics profiling shows BAP1 loss is associated with upregulated cell adhesion molecules in uveal melanoma. Molecular Cancer Research, 20(8), 1260\u20131271.","journal-title":"Molecular Cancer Research"},{"issue":"5","key":"10298_CR35","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1091\/mbc.E20-04-0241","volume":"32","author":"MD Onken","year":"2021","unstructured":"Onken, M. D., Blumer, K. J., & Cooper, J. A. (2021). Uveal melanoma cells use ameboid and mesenchymal mechanisms of cell motility crossing the endothelium. Molecular Biology of The Cell, 32(5), 413\u2013421.","journal-title":"Molecular Biology of The Cell"},{"issue":"5","key":"10298_CR36","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.2353\/ajpath.2007.060886","volume":"170","author":"P Auguste","year":"2007","unstructured":"Auguste, P., et al. (2007). The host inflammatory response promotes liver metastasis by increasing tumor cell arrest and extravasation. The American Journal of Pathology, 170(5), 1781\u20131792.","journal-title":"The American Journal of Pathology"},{"issue":"4","key":"10298_CR37","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1158\/1535-7163.MCT-19-0098","volume":"19","author":"S Piperno-Neumann","year":"2020","unstructured":"Piperno-Neumann, S., et al. (2020). Genomic profiling of metastatic uveal melanoma and clinical results of a phase I study of the protein kinase C inhibitor AEB071. Molecular Cancer Therapeutics, 19(4), 1031\u20131039.","journal-title":"Molecular Cancer Therapeutics"},{"issue":"5","key":"10298_CR38","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1158\/1535-7163.MCT-13-0550","volume":"13","author":"E Musi","year":"2014","unstructured":"Musi, E., et al. (2014). The phosphoinositide 3-kinase alpha selective inhibitor BYL719 enhances the effect of the protein kinase C inhibitor AEB071 in GNAQ\/GNA11-mutant uveal melanoma cells. Molecular Cancer Therapeutics, 13(5), 1044\u20131053.","journal-title":"Molecular Cancer Therapeutics"},{"key":"10298_CR39","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1192840","volume":"14","author":"X Cai","year":"2023","unstructured":"Cai, X., et al. (2023). Cholangiokines: Undervalued modulators in the hepatic microenvironment. Frontiers in Immunology, 14, Article 1192840.","journal-title":"Frontiers in Immunology"},{"issue":"1","key":"10298_CR40","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1097\/CMR.0000000000000701","volume":"31","author":"R Bao","year":"2021","unstructured":"Bao, R., et al. (2021). Transcriptional analysis of metastatic uveal melanoma survival nominates NRP1 as a therapeutic target. Melanoma Research, 31(1), 27\u201337.","journal-title":"Melanoma Research"},{"issue":"3","key":"10298_CR41","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1167\/iovs.65.3.37","volume":"65","author":"C Gong","year":"2024","unstructured":"Gong, C., et al. (2024). IL-6-driven autocrine lactate promotes immune escape of uveal melanoma. Investigative Ophthalmology & Visual Science, 65(3), 37.","journal-title":"Investigative Ophthalmology & Visual Science"},{"key":"10298_CR42","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/S0083-6729(06)75006-3","volume":"75","author":"H Senoo","year":"2007","unstructured":"Senoo, H., Kojima, N., & Sato, M. (2007). Vitamin A-storing cells (stellate cells). Vitamins And Hormones, 75, 131\u2013159.","journal-title":"Vitamins And Hormones"},{"key":"10298_CR43","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2020.00709","volume":"8","author":"AE Barry","year":"2020","unstructured":"Barry, A. E., et al. (2020). Hepatic stellate cells and hepatocarcinogenesis. Frontiers in Cell and Developmental Biology, 8, Article 709.","journal-title":"Frontiers in Cell and Developmental Biology"},{"key":"10298_CR44","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11081043","author":"L Piquet","year":"2019","unstructured":"Piquet, L., et al. (2019). Synergic interactions between hepatic stellate cells and uveal melanoma in metastatic growth. Cancers. https:\/\/doi.org\/10.3390\/cancers11081043","journal-title":"Cancers"},{"issue":"2","key":"10298_CR45","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1167\/iovs.07-0975","volume":"49","author":"M Ye","year":"2008","unstructured":"Ye, M., et al. (2008). Involvement of PI3K\/Akt signaling pathway in hepatocyte growth factor-induced migration of uveal melanoma cells. Investigative Ophthalmology & Visual Science, 49(2), 497\u2013504.","journal-title":"Investigative Ophthalmology & Visual Science"},{"issue":"9","key":"10298_CR46","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0073312","volume":"8","author":"G Yu","year":"2013","unstructured":"Yu, G., et al. (2013). Hepatic stellate cells secreted hepatocyte growth factor contributes to the chemoresistance of hepatocellular carcinoma. PLoS One, 8(9), Article e73312.","journal-title":"PLoS One"},{"key":"10298_CR47","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.exer.2019.02.012","volume":"181","author":"N Babchia","year":"2019","unstructured":"Babchia, N., et al. (2019). The bidirectional crosstalk between metastatic uveal melanoma cells and hepatic stellate cells engenders an inflammatory microenvironment. Experimental Eye Research, 181, 213\u2013222.","journal-title":"Experimental Eye Research"},{"key":"10298_CR48","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.humpath.2016.07.012","volume":"57","author":"HE Grossniklaus","year":"2016","unstructured":"Grossniklaus, H. E., et al. (2016). Metastatic ocular melanoma to the liver exhibits infiltrative and nodular growth patterns. Human Pathology, 57, 165\u2013175.","journal-title":"Human Pathology"},{"issue":"4","key":"10298_CR49","first-page":"227","volume":"4","author":"R Barnhill","year":"2018","unstructured":"Barnhill, R., et al. (2018). Replacement and desmoplastic histopathological growth patterns: A pilot study of prediction of outcome in patients with uveal melanoma liver metastases. The Journal of Pathology: Clinical Research, 4(4), 227\u2013240.","journal-title":"The Journal of Pathology: Clinical Research"},{"issue":"10","key":"10298_CR50","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1038\/s41416-020-0812-z","volume":"122","author":"S Stremitzer","year":"2020","unstructured":"Stremitzer, S., et al. (2020). Immune phenotype and histopathological growth pattern in patients with colorectal liver metastases. British Journal of Cancer, 122(10), 1518\u20131524.","journal-title":"British Journal of Cancer"},{"key":"10298_CR51","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13215316","author":"S Yavuzyigitoglu","year":"2021","unstructured":"Yavuzyigitoglu, S., et al. (2021). Radiological patterns of uveal melanoma liver metastases in correlation to genetic status. Cancers. https:\/\/doi.org\/10.3390\/cancers13215316","journal-title":"Cancers"},{"issue":"1","key":"10298_CR52","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1159\/000541341","volume":"17","author":"NA Eide","year":"2024","unstructured":"Eide, N. A., et al. (2024). Delayed distant recurrence of a uveal melanoma 4 decades after enucleation. Case Reports in Oncology, 17(1), 1131\u20131139.","journal-title":"Case Reports in Oncology"},{"issue":"4","key":"10298_CR53","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1001\/jamaophthalmol.2013.2547","volume":"131","author":"HE Grossniklaus","year":"2013","unstructured":"Grossniklaus, H. E. (2013). Progression of ocular melanoma metastasis to the liver: The 2012 Zimmerman lecture. JAMA Ophthalmology, 131(4), 462\u2013469.","journal-title":"JAMA Ophthalmology"},{"issue":"1","key":"10298_CR54","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1111\/j.1755-148X.2009.00647.x","volume":"23","author":"L Ossowski","year":"2010","unstructured":"Ossowski, L., & Aguirre-Ghiso, J. A. (2010). Dormancy of metastatic melanoma. Pigment Cell & Melanoma Research, 23(1), 41\u201356.","journal-title":"Pigment Cell & Melanoma Research"},{"issue":"6","key":"10298_CR55","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1038\/sj.eye.6702322","volume":"21","author":"SA Callejo","year":"2007","unstructured":"Callejo, S. A., et al. (2007). Identification of circulating malignant cells and its correlation with prognostic factors and treatment in uveal melanoma. A prospective longitudinal study. Eye, 21(6), 752\u2013759.","journal-title":"Eye"},{"issue":"2","key":"10298_CR56","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1093\/ajcp\/aqad029","volume":"160","author":"VT Gill","year":"2023","unstructured":"Gill, V. T., et al. (2023). Multiorgan involvement of dormant uveal melanoma micrometastases in postmortem tissue from patients without coexisting macrometastases. American Journal of Clinical Pathology, 160(2), 164\u2013174.","journal-title":"American Journal of Clinical Pathology"},{"issue":"15","key":"10298_CR57","doi-asserted-by":"publisher","first-page":"3741","DOI":"10.1158\/1078-0432.CCR-17-1703","volume":"24","author":"Y Jin","year":"2018","unstructured":"Jin, Y., et al. (2018). Neddylation blockade diminishes hepatic metastasis by dampening cancer stem-like cells and angiogenesis in uveal melanoma. Clinical Cancer Research, 24(15), 3741\u20133754.","journal-title":"Clinical Cancer Research"},{"issue":"6","key":"10298_CR58","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1038\/s41416-022-01859-7","volume":"127","author":"E Latacz","year":"2022","unstructured":"Latacz, E., et al. (2022). Histopathological growth patterns of liver metastasis: Updated consensus guidelines for pattern scoring, perspectives and recent mechanistic insights. British Journal of Cancer, 127(6), 988\u20131013.","journal-title":"British Journal of Cancer"},{"issue":"5","key":"10298_CR59","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1016\/j.ophtha.2016.01.023","volume":"123","author":"S Yavuzyigitoglu","year":"2016","unstructured":"Yavuzyigitoglu, S., et al. (2016). Uveal melanomas with SF3B1 mutations: A distinct subclass associated with late-onset metastases. Ophthalmology, 123(5), 1118\u20131128.","journal-title":"Ophthalmology"},{"issue":"10","key":"10298_CR60","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1158\/2159-8290.CD-13-0330","volume":"3","author":"SJ Furney","year":"2013","unstructured":"Furney, S. J., et al. (2013). SF3B1 mutations are associated with alternative splicing in uveal melanoma. Cancer Discovery, 3(10), 1122\u20131129.","journal-title":"Cancer Discovery"},{"issue":"8","key":"10298_CR61","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1158\/2159-8290.CD-20-0555","volume":"11","author":"J Bigot","year":"2021","unstructured":"Bigot, J., et al. (2021). Splicing patterns in SF3B1-mutated uveal melanoma generate shared immunogenic tumor-specific neoepitopes. Cancer Discovery, 11(8), 1938\u20131951.","journal-title":"Cancer Discovery"},{"issue":"6009","key":"10298_CR62","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1126\/science.1194472","volume":"330","author":"JW Harbour","year":"2010","unstructured":"Harbour, J. W., et al. (2010). Frequent mutation of BAP1 in metastasizing uveal melanomas. Science, 330(6009), 1410\u20131413.","journal-title":"Science"},{"issue":"2","key":"10298_CR63","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/ng.2523","volume":"45","author":"JW Harbour","year":"2013","unstructured":"Harbour, J. W., et al. (2013). Recurrent mutations at codon 625 of the splicing factor SF3B1 in uveal melanoma. Nature Genetics, 45(2), 133\u2013135.","journal-title":"Nature Genetics"},{"issue":"3","key":"10298_CR64","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/nrc3459","volume":"13","author":"M Carbone","year":"2013","unstructured":"Carbone, M., et al. (2013). BAP1 and cancer. Nature Reviews. Cancer, 13(3), 153\u2013159.","journal-title":"Nature Reviews. Cancer"},{"issue":"2","key":"10298_CR65","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1038\/s41418-020-00709-4","volume":"28","author":"L Masclef","year":"2021","unstructured":"Masclef, L., et al. (2021). Roles and mechanisms of BAP1 deubiquitinase in tumor suppression. Cell Death and Differentiation, 28(2), 606\u2013625.","journal-title":"Cell Death and Differentiation"},{"issue":"2","key":"10298_CR66","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.joco.2018.02.005","volume":"30","author":"B Masoomian","year":"2018","unstructured":"Masoomian, B., Shields, J. A., & Shields, C. L. (2018). Overview of BAP1 cancer predisposition syndrome and the relationship to uveal melanoma. Journal of Current Ophthalmology, 30(2), 102\u2013109.","journal-title":"Journal of Current Ophthalmology"},{"issue":"2","key":"10298_CR67","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1097\/PAT.0b013e32835d0efb","volume":"45","author":"R Murali","year":"2013","unstructured":"Murali, R., Wiesner, T., & Scolyer, R. A. (2013). Tumours associated with BAP1 mutations. Pathology, 45(2), 116\u2013126.","journal-title":"Pathology"},{"issue":"8","key":"10298_CR68","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1001\/jamaophthalmol.2015.1119","volume":"133","author":"MP Gupta","year":"2015","unstructured":"Gupta, M. P., et al. (2015). Clinical characteristics of uveal melanoma in patients with germline BAP1 mutations. JAMA Ophthalmology, 133(8), 881\u2013887.","journal-title":"JAMA Ophthalmology"},{"issue":"1","key":"10298_CR69","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-88390-6","volume":"11","author":"OE Uner","year":"2021","unstructured":"Uner, O. E., et al. (2021). Estimation of the timing of BAP1 mutation in uveal melanoma progression. Scientific Reports, 11(1), Article 8923.","journal-title":"Scientific Reports"},{"issue":"6","key":"10298_CR70","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1002\/jso.23535","volume":"109","author":"D Gomez","year":"2014","unstructured":"Gomez, D., et al. (2014). The liverpool uveal melanoma liver metastases pathway: Outcome following liver resection. Journal of Surgical Oncology, 109(6), 542\u2013547.","journal-title":"Journal of Surgical Oncology"},{"issue":"3","key":"10298_CR71","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1097\/CMR.0000000000000728","volume":"31","author":"ES Rantala","year":"2021","unstructured":"Rantala, E. S., Kivela, T. T., & Hernberg, M. M. (2021). Impact of staging on survival outcomes: A nationwide real-world cohort study of metastatic uveal melanoma. Melanoma Research, 31(3), 224\u2013231.","journal-title":"Melanoma Research"},{"key":"10298_CR72","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.ajo.2016.06.002","volume":"168","author":"TT Kivela","year":"2016","unstructured":"Kivela, T. T., et al. (2016). Validation of a prognostic staging for metastatic uveal melanoma: A collaborative study of the European Ophthalmic Oncology Group. American Journal of Ophthalmology, 168, 217\u2013226.","journal-title":"American Journal of Ophthalmology"},{"issue":"1","key":"10298_CR73","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1097\/CMR.0000000000000867","volume":"33","author":"DB Trivedi","year":"2023","unstructured":"Trivedi, D. B., et al. (2023). Liver resection for metastatic uveal melanoma: Experience from a supra-regional centre and review of literature. Melanoma Research, 33(1), 71\u201379.","journal-title":"Melanoma Research"},{"issue":"7","key":"10298_CR74","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1002\/1097-0142(20001001)89:7<1561::AID-CNCR21>3.0.CO;2-R","volume":"89","author":"T Aoyama","year":"2000","unstructured":"Aoyama, T., et al. (2000). Protracted survival after resection of metastatic uveal melanoma. Cancer, 89(7), 1561\u20131568.","journal-title":"Cancer"},{"issue":"6","key":"10298_CR75","doi-asserted-by":"publisher","first-page":"2567","DOI":"10.1007\/s00464-015-4527-9","volume":"30","author":"M Akyuz","year":"2016","unstructured":"Akyuz, M., et al. (2016). Laparoscopic management of liver metastases from uveal melanoma. Surgical Endoscopy, 30(6), 2567\u20132571.","journal-title":"Surgical Endoscopy"},{"issue":"1","key":"10298_CR76","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1002\/cncr.11872","volume":"100","author":"EC Hsueh","year":"2004","unstructured":"Hsueh, E. C., et al. (2004). Prolonged survival after complete resection of metastases from intraocular melanoma. Cancer, 100(1), 122\u2013129.","journal-title":"Cancer"},{"issue":"7","key":"10298_CR77","doi-asserted-by":"publisher","first-page":"4989","DOI":"10.1245\/s10434-025-17115-0","volume":"32","author":"M Maspero","year":"2025","unstructured":"Maspero, M., et al. (2025). Intention-to-treat analysis of hepatic resection for liver metastases from uveal melanoma: A single-center experience. Annals of Surgical Oncology, 32(7), 4989\u20134996.","journal-title":"Annals of Surgical Oncology"},{"issue":"9","key":"10298_CR78","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1038\/ng.2359","volume":"44","author":"M Krauthammer","year":"2012","unstructured":"Krauthammer, M., et al. (2012). Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. Nature Genetics, 44(9), 1006\u20131014.","journal-title":"Nature Genetics"},{"key":"10298_CR79","doi-asserted-by":"publisher","DOI":"10.1177\/1758834018757175","volume":"10","author":"J Yang","year":"2018","unstructured":"Yang, J., et al. (2018). Treatment of uveal melanoma: Where are we now? Therapeutic Advances in Medical Oncology, 10, Article 1758834018757175.","journal-title":"Therapeutic Advances in Medical Oncology"},{"issue":"9","key":"10298_CR80","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1001\/jamaophthalmol.2018.1813","volume":"136","author":"DB Johnson","year":"2018","unstructured":"Johnson, D. B., & Daniels, A. B. (2018). Continued poor survival in metastatic uveal melanoma: Implications for molecular prognostication, surveillance imaging, adjuvant therapy, and clinical trials. JAMA Ophthalmology, 136(9), 986\u2013988.","journal-title":"JAMA Ophthalmology"},{"issue":"21","key":"10298_CR81","doi-asserted-by":"publisher","first-page":"3344","DOI":"10.1002\/cncr.30258","volume":"122","author":"AP Algazi","year":"2016","unstructured":"Algazi, A. P., et al. (2016). Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies. Cancer, 122(21), 3344\u20133353.","journal-title":"Cancer"},{"key":"10298_CR82","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11081048","author":"TE Schank","year":"2019","unstructured":"Schank, T. E., & Hassel, J. C. (2019). Immunotherapies for the treatment of uveal melanoma-History and future. Cancers. https:\/\/doi.org\/10.3390\/cancers11081048","journal-title":"Cancers"},{"key":"10298_CR83","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11101489","author":"KF Bol","year":"2019","unstructured":"Bol, K. F., et al. (2019). Real-world impact of immune checkpoint inhibitors in metastatic uveal melanoma. Cancers. https:\/\/doi.org\/10.3390\/cancers11101489","journal-title":"Cancers"},{"issue":"1","key":"10298_CR84","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0800-0","volume":"7","author":"MV Heppt","year":"2019","unstructured":"Heppt, M. V., et al. (2019). Combined immune checkpoint blockade for metastatic uveal melanoma: A retrospective, multi-center study. Journal for Immunotherapy of Cancer, 7(1), Article 299.","journal-title":"Journal for Immunotherapy of Cancer"},{"key":"10298_CR85","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000331","author":"YG Najjar","year":"2020","unstructured":"Najjar, Y. G., et al. (2020). Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: A multicenter, retrospective study. Journal for Immunotherapy of Cancer. https:\/\/doi.org\/10.1136\/jitc-2019-000331","journal-title":"Journal for Immunotherapy of Cancer"},{"issue":"6","key":"10298_CR86","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1200\/JCO.20.00550","volume":"39","author":"JM Piulats","year":"2021","unstructured":"Piulats, J. M., et al. (2021). Nivolumab plus ipilimumab for treatment-naive metastatic uveal melanoma: An open-label, multicenter, phase II trial by the Spanish Multidisciplinary Melanoma Group (GEM-1402). Journal of Clinical Oncology, 39(6), 586\u2013598.","journal-title":"Journal of Clinical Oncology"},{"issue":"6","key":"10298_CR87","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1200\/JCO.20.00605","volume":"39","author":"MS Pelster","year":"2021","unstructured":"Pelster, M. S., et al. (2021). Nivolumab and ipilimumab in metastatic uveal melanoma: Results from a single-arm phase II study. Journal of Clinical Oncology, 39(6), 599\u2013607.","journal-title":"Journal of Clinical Oncology"},{"key":"10298_CR88","doi-asserted-by":"publisher","first-page":"S741","DOI":"10.1016\/j.annonc.2024.08.1194","volume":"35","author":"J Lutzky","year":"2024","unstructured":"Lutzky, J., et al. (2024). 1126P A phase II study of nivolumab\/relatlimab in metastatic uveal melanoma. Annals of Oncology, 35, S741.","journal-title":"Annals of Oncology"},{"key":"10298_CR89","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyaf173","author":"A Ciernik","year":"2025","unstructured":"Ciernik, A., et al. (2025). Retrospective multicenter analysis of real-life toxicity and outcome of ipilimumab and nivolumab in metastatic uveal melanoma. The Oncologist. https:\/\/doi.org\/10.1093\/oncolo\/oyaf173","journal-title":"The Oncologist"},{"issue":"1","key":"10298_CR90","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-46906-4","volume":"15","author":"S Leonard-Murali","year":"2024","unstructured":"Leonard-Murali, S., et al. (2024). Uveal melanoma immunogenomics predict immunotherapy resistance and susceptibility. Nature Communications, 15(1), Article 2863.","journal-title":"Nature Communications"},{"key":"10298_CR91","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12020405","author":"M Terai","year":"2020","unstructured":"Terai, M., et al. (2020). Expression of tryptophan 2,3-dioxygenase in metastatic uveal melanoma. Cancers. https:\/\/doi.org\/10.3390\/cancers12020405","journal-title":"Cancers"},{"issue":"1","key":"10298_CR92","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-14256-1","volume":"11","author":"MA Durante","year":"2020","unstructured":"Durante, M. A., et al. (2020). Single-cell analysis reveals new evolutionary complexity in uveal melanoma. Nature Communications, 11(1), Article 496.","journal-title":"Nature Communications"},{"issue":"4","key":"10298_CR93","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.exer.2010.06.025","volume":"91","author":"J Ma","year":"2010","unstructured":"Ma, J., et al. (2010). Human uveal melanoma cells inhibit the immunostimulatory function of dendritic cells. Experimental Eye Research, 91(4), 491\u2013499.","journal-title":"Experimental Eye Research"},{"issue":"13","key":"10298_CR94","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1056\/NEJMoa2103485","volume":"385","author":"P Nathan","year":"2021","unstructured":"Nathan, P., et al. (2021). Overall survival benefit with tebentafusp in metastatic uveal melanoma. New England Journal of Medicine, 385(13), 1196\u20131206.","journal-title":"New England Journal of Medicine"},{"issue":"22","key":"10298_CR95","doi-asserted-by":"publisher","first-page":"5869","DOI":"10.1158\/1078-0432.CCR-20-1247","volume":"26","author":"MR Middleton","year":"2020","unstructured":"Middleton, M. R., et al. (2020). Tebentafusp, a TCR\/anti-CD3 bispecific fusion protein targeting gp100, potently activated antitumor immune responses in patients with metastatic melanoma. Clinical Cancer Research, 26(22), 5869\u20135878.","journal-title":"Clinical Cancer Research"},{"issue":"10","key":"10298_CR96","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1080\/14737140.2022.2124971","volume":"22","author":"LN Chen","year":"2022","unstructured":"Chen, L. N., & Carvajal, R. D. (2022). Tebentafusp for the treatment of HLA-A*02: 01-positive adult patients with unresectable or metastatic uveal melanoma. Expert Review Of Anticancer Therapy, 22(10), 1017\u20131027.","journal-title":"Expert Review Of Anticancer Therapy"},{"key":"10298_CR97","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-009028","author":"JJ Sacco","year":"2024","unstructured":"Sacco, J. J., et al. (2024). Long-term survival follow-up for tebentafusp in previously treated metastatic uveal melanoma. Journal for Immunotherapy of Cancer. https:\/\/doi.org\/10.1136\/jitc-2024-009028","journal-title":"Journal for Immunotherapy of Cancer"},{"issue":"11","key":"10298_CR98","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1097\/PAS.0000000000001134","volume":"42","author":"C Lezcano","year":"2018","unstructured":"Lezcano, C., et al. (2018). PRAME expression in melanocytic tumors. American Journal of Surgical Pathology, 42(11), 1456\u20131465.","journal-title":"American Journal of Surgical Pathology"},{"issue":"5","key":"10298_CR99","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1158\/1078-0432.CCR-15-2071","volume":"22","author":"MG Field","year":"2016","unstructured":"Field, M. G., et al. (2016). PRAME as an independent biomarker for metastasis in uveal melanoma. Clinical Cancer Research, 22(5), 1234\u20131242.","journal-title":"Clinical Cancer Research"},{"key":"10298_CR100","doi-asserted-by":"publisher","first-page":"S875","DOI":"10.1016\/j.annonc.2022.07.854","volume":"33","author":"O Hamid","year":"2022","unstructured":"Hamid, O., et al. (2022). 728O results from phase I dose escalation of IMC-F106C, the first PRAME & #xd7; CD3 immtac bispecific protein in solid tumors. Annals Of Oncology, 33, S875.","journal-title":"Annals Of Oncology"},{"issue":"7","key":"10298_CR101","doi-asserted-by":"publisher","first-page":"717","DOI":"10.6004\/jadpro.2022.13.7.8","volume":"13","author":"G Hua","year":"2022","unstructured":"Hua, G., Carlson, D., & Starr, J. R. (2022). Tebentafusp-tebn: A novel bispecific T-cell engager for metastatic uveal melanoma. Journal of Advanced Practitioner Oncology, 13(7), 717\u2013723.","journal-title":"Journal of Advanced Practitioner Oncology"},{"issue":"6","key":"10298_CR102","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/S1470-2045(17)30251-6","volume":"18","author":"SS Chandran","year":"2017","unstructured":"Chandran, S. S., et al. (2017). Treatment of metastatic uveal melanoma with adoptive transfer of tumour-infiltrating lymphocytes: A single-centre, two-stage, single-arm, phase 2 study. The Lancet Oncology, 18(6), 792\u2013802.","journal-title":"The Lancet Oncology"},{"key":"10298_CR103","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03731-6","author":"M Wermke","year":"2025","unstructured":"Wermke, M., et al. (2025). Author correction: Autologous T cell therapy for PRAME+ advanced solid tumors in HLA-A*02+ patients: A phase 1 trial. Nature Medicine. https:\/\/doi.org\/10.1038\/s41591-025-03731-6","journal-title":"Nature Medicine"},{"issue":"16_suppl","key":"10298_CR104","doi-asserted-by":"publisher","first-page":"9527","DOI":"10.1200\/JCO.2023.41.16_suppl.9527","volume":"41","author":"JJ Sacco","year":"2023","unstructured":"Sacco, J. J., et al. (2023). Preliminary safety and efficacy results from an open-label, multicenter, phase 1 study of RP2 as a single agent and in combination with nivolumab in a cohort of patients with uveal melanoma. Journal of Clinical Oncology, 41(16_suppl), 9527\u20139527.","journal-title":"Journal of Clinical Oncology"},{"issue":"9","key":"10298_CR105","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1089\/hum.2010.020","volume":"21","author":"SK Geevarghese","year":"2010","unstructured":"Geevarghese, S. K., et al. (2010). Phase I\/II study of oncolytic herpes simplex virus NV1020 in patients with extensively pretreated refractory colorectal cancer metastatic to the liver. Human Gene Therapy, 21(9), 1119\u20131128.","journal-title":"Human Gene Therapy"},{"issue":"2","key":"10298_CR106","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1096\/fasebj.14.2.301","volume":"14","author":"SS Yoon","year":"2000","unstructured":"Yoon, S. S., et al. (2000). An oncolytic herpes simplex virus type 1 selectively destroys diffuse liver metastases from colon carcinoma. FASEB Journal, 14(2), 301\u2013311.","journal-title":"FASEB Journal"},{"issue":"8","key":"10298_CR107","doi-asserted-by":"publisher","first-page":"5340","DOI":"10.1245\/s10434-024-15293-x","volume":"31","author":"JS Zager","year":"2024","unstructured":"Zager, J. S., et al. (2024). Efficacy and safety of the melphalan\/hepatic delivery system in patients with unresectable metastatic uveal melanoma: Results from an open-label, single-arm, multicenter phase 3 study. Annals Of Surgical Oncology, 31(8), 5340\u20135351.","journal-title":"Annals Of Surgical Oncology"},{"issue":"2","key":"10298_CR108","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1245\/s10434-020-08741-x","volume":"28","author":"TS Meijer","year":"2021","unstructured":"Meijer, T. S., et al. (2021). Percutaneous hepatic perfusion with melphalan in patients with unresectable ocular melanoma metastases confined to the liver: A prospective phase II study. Annals of Surgical Oncology, 28(2), 1130\u20131141.","journal-title":"Annals of Surgical Oncology"},{"issue":"3","key":"10298_CR109","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1007\/s00270-022-03338-1","volume":"46","author":"TML Tong","year":"2023","unstructured":"Tong, T. M. L., et al. (2023). Combining melphalan percutaneous hepatic perfusion with ipilimumab plus nivolumab in advanced uveal melanoma: First safety and efficacy data from the phase Ib part of the Chopin Trial. Cardiovascular and Interventional Radiology, 46(3), 350\u2013359.","journal-title":"Cardiovascular and Interventional Radiology"},{"key":"10298_CR110","doi-asserted-by":"publisher","unstructured":"Lapadula, D., & Benovic, J. L. (2021). Targeting oncogenic G\u03b1q\/11 in uveal melanoma. Cancers, 13(24), 6195. https:\/\/doi.org\/10.3390\/cancers13246195","DOI":"10.3390\/cancers13246195"},{"issue":"1","key":"10298_CR111","doi-asserted-by":"publisher","DOI":"10.1007\/s10928-024-09956-1","volume":"52","author":"E Khera","year":"2024","unstructured":"Khera, E., et al. (2024). QSP modeling of a transiently inactivating antibody-drug conjugate highlights benefit of short antibody half life. Journal of Pharmacokinetics and Pharmacodynamics, 52(1), Article 7.","journal-title":"Journal of Pharmacokinetics and Pharmacodynamics"},{"issue":"39","key":"10298_CR112","doi-asserted-by":"publisher","first-page":"4724","DOI":"10.1038\/onc.2013.418","volume":"33","author":"X Chen","year":"2014","unstructured":"Chen, X., et al. (2014). Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations. Oncogene, 33(39), 4724\u20134734.","journal-title":"Oncogene"},{"issue":"9","key":"10298_CR113","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1158\/1535-7163.MCT-12-0121","volume":"11","author":"X Wu","year":"2012","unstructured":"Wu, X., et al. (2012). Protein kinase C inhibitor AEB071 targets ocular melanoma harboring GNAQ mutations via effects on the PKC\/Erk1\/2 and PKC\/NF-kappaB pathways. Molecular Cancer Therapeutics, 11(9), 1905\u20131914.","journal-title":"Molecular Cancer Therapeutics"},{"issue":"10","key":"10298_CR114","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1038\/s41416-023-02199-w","volume":"128","author":"A Rodrigues","year":"2023","unstructured":"Rodrigues, A., Cosman, R., & Joshua, A. M. (2023). LXS196 for metastatic uveal melanoma - Finally some progress. British Journal of Cancer, 128(10), 1791\u20131793.","journal-title":"British Journal of Cancer"},{"issue":"11","key":"10298_CR115","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.101244","volume":"4","author":"N Arang","year":"2023","unstructured":"Arang, N., et al. (2023). High-throughput chemogenetic drug screening reveals PKC-RhoA\/PKN as a targetable signaling vulnerability in GNAQ-driven uveal melanoma. Cell Reports Medicine, 4(11), Article 101244.","journal-title":"Cell Reports Medicine"},{"key":"10298_CR116","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1232787","volume":"14","author":"L Cao","year":"2023","unstructured":"Cao, L., et al. (2023). Darovasertib, a novel treatment for metastatic uveal melanoma. Frontiers in Pharmacology, 14, Article 1232787.","journal-title":"Frontiers in Pharmacology"},{"issue":"2","key":"10298_CR117","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1021\/acs.jmedchem.3c02002","volume":"67","author":"M Visser","year":"2024","unstructured":"Visser, M., et al. (2024). Discovery of Darovasertib (NVP-LXS196), a pan-PKC inhibitor for the treatment of metastatic uveal melanoma. Journal of Medicinal Chemistry, 67(2), 1447\u20131459.","journal-title":"Journal of Medicinal Chemistry"},{"key":"10298_CR118","doi-asserted-by":"publisher","first-page":"S651","DOI":"10.1016\/j.annonc.2023.09.2215","volume":"34","author":"M McKean","year":"2023","unstructured":"McKean, M., et al. (2023). 1081o ctDNA reduction and clinical efficacy of the darovasertib + crizotinib (daro + crizo) combination in metastatic uveal melanoma (MUM). Annals Of Oncology, 34, S651.","journal-title":"Annals Of Oncology"},{"key":"10298_CR119","doi-asserted-by":"publisher","DOI":"10.1038\/srep44564","volume":"7","author":"P Fagone","year":"2017","unstructured":"Fagone, P., et al. (2017). Identification of novel chemotherapeutic strategies for metastatic uveal melanoma. Scientific Reports, 7, Article 44564.","journal-title":"Scientific Reports"},{"key":"10298_CR120","doi-asserted-by":"publisher","DOI":"10.1101\/mcs.a006111","author":"W Lin","year":"2021","unstructured":"Lin, W., et al. (2021). Intra- and intertumoral heterogeneity of liver metastases in a patient with uveal melanoma revealed by single-cell RNA sequencing. Molecular Case Studies. https:\/\/doi.org\/10.1101\/mcs.a006111","journal-title":"Molecular Case Studies"},{"issue":"1","key":"10298_CR121","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1186\/s13046-021-01947-1","volume":"40","author":"A Tosi","year":"2021","unstructured":"Tosi, A., et al. (2021). The immune cell landscape of metastatic uveal melanoma correlates with overall survival. Journal of Experimental & Clinical Cancer Research, 40(1), 154.","journal-title":"Journal of Experimental & Clinical Cancer Research"},{"key":"10298_CR122","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14133094","author":"Y Fu","year":"2022","unstructured":"Fu, Y., Xiao, W., & Mao, Y. (2022). Recent advances and challenges in uveal melanoma immunotherapy. Cancers. https:\/\/doi.org\/10.3390\/cancers14133094","journal-title":"Cancers"},{"issue":"20","key":"10298_CR123","doi-asserted-by":"publisher","first-page":"2445","DOI":"10.1042\/CS20190654","volume":"135","author":"ML Cheng","year":"2021","unstructured":"Cheng, M. L., et al. (2021). The immune niche of the liver. Clinical Science, 135(20), 2445\u20132466.","journal-title":"Clinical Science"},{"issue":"3","key":"10298_CR124","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1038\/cmi.2016.3","volume":"13","author":"MW Robinson","year":"2016","unstructured":"Robinson, M. W., Harmon, C., & O\u2019Farrelly, C. (2016). Liver immunology and its role in inflammation and homeostasis. Cellular and Molecular Immunology, 13(3), 267\u2013276.","journal-title":"Cellular and Molecular Immunology"},{"issue":"3","key":"10298_CR125","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1038\/cmi.2016.4","volume":"13","author":"Z Shuai","year":"2016","unstructured":"Shuai, Z., et al. (2016). Adaptive immunity in the liver. Cellular And Molecular Immunology, 13(3), 354\u2013368.","journal-title":"Cellular And Molecular Immunology"},{"issue":"1","key":"10298_CR126","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2020.1854519","volume":"9","author":"J Johansson","year":"2020","unstructured":"Johansson, J., et al. (2020). Presence of tumor-infiltrating CD8(+) T cells and macrophages correlates to longer overall survival in patients undergoing isolated hepatic perfusion for uveal melanoma liver metastasis. Oncoimmunology, 9(1), Article 1854519.","journal-title":"Oncoimmunology"},{"issue":"9","key":"10298_CR127","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1038\/s41423-020-0504-x","volume":"17","author":"D Kabelitz","year":"2020","unstructured":"Kabelitz, D., et al. (2020). Cancer immunotherapy with gammadelta T cells: Many paths ahead of us. Cellular and Molecular Immunology, 17(9), 925\u2013939.","journal-title":"Cellular and Molecular Immunology"},{"key":"10298_CR128","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.848455","volume":"13","author":"X Lv","year":"2022","unstructured":"Lv, X., Ding, M., & Liu, Y. (2022). Landscape of infiltrated immune cell characterization in uveal melanoma to improve immune checkpoint blockade therapy. Frontiers in Immunology, 13, Article 848455.","journal-title":"Frontiers in Immunology"},{"key":"10298_CR129","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.713569","volume":"9","author":"H Zhao","year":"2021","unstructured":"Zhao, H., et al. (2021). Identification of immune cell infiltration landscape and their prognostic significance in uveal melanoma. Frontiers in Cell and Developmental Biology, 9, Article 713569.","journal-title":"Frontiers in Cell and Developmental Biology"},{"issue":"7","key":"10298_CR130","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/S1471-4906(03)00162-5","volume":"24","author":"M Emoto","year":"2003","unstructured":"Emoto, M., & Kaufmann, S. H. (2003). Liver NKT cells: An account of heterogeneity. Trends in Immunology, 24(7), 364\u2013369.","journal-title":"Trends in Immunology"},{"issue":"3","key":"10298_CR131","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/cmi.2015.115","volume":"13","author":"K Bandyopadhyay","year":"2016","unstructured":"Bandyopadhyay, K., Marrero, I., & Kumar, V. (2016). NKT cell subsets as key participants in liver physiology and pathology. Cellular and Molecular Immunology, 13(3), 337\u2013346.","journal-title":"Cellular and Molecular Immunology"},{"issue":"3","key":"10298_CR132","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.jhep.2013.02.032","volume":"59","author":"V Kumar","year":"2013","unstructured":"Kumar, V. (2013). NKT-cell subsets: Promoters and protectors in inflammatory liver disease. Journal of Hepatology, 59(3), 618\u2013620.","journal-title":"Journal of Hepatology"},{"issue":"5","key":"10298_CR133","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/s41419-024-06726-2","volume":"15","author":"K Wu","year":"2024","unstructured":"Wu, K., et al. (2024). Role of T cells in liver metastasis. Cell Death & Disease, 15(5), 341.","journal-title":"Cell Death & Disease"},{"issue":"6","key":"10298_CR134","doi-asserted-by":"publisher","first-page":"3094","DOI":"10.1167\/iovs.10-7067","volume":"52","author":"W Yang","year":"2011","unstructured":"Yang, W., et al. (2011). NKT cell exacerbation of liver metastases arising from melanomas transplanted into either the eyes or spleens of mice. Investigative Ophthalmology & Visual Science, 52(6), 3094\u20133102.","journal-title":"Investigative Ophthalmology & Visual Science"},{"issue":"5","key":"10298_CR135","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1038\/nri.2017.11","volume":"17","author":"O Krenkel","year":"2017","unstructured":"Krenkel, O., & Tacke, F. (2017). Liver macrophages in tissue homeostasis and disease. Nature Reviews Immunology, 17(5), 306\u2013321.","journal-title":"Nature Reviews Immunology"},{"key":"10298_CR136","doi-asserted-by":"publisher","DOI":"10.1017\/S1462399411002110","volume":"14","author":"X Gu","year":"2012","unstructured":"Gu, X., & Manautou, J. E. (2012). Molecular mechanisms underlying chemical liver injury. Expert Reviews in Molecular Medicine, 14, Article e4.","journal-title":"Expert Reviews in Molecular Medicine"},{"key":"10298_CR137","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.803037","volume":"12","author":"C Wang","year":"2021","unstructured":"Wang, C., et al. (2021). Macrophage polarization and its role in liver disease. Frontiers in Immunology, 12, Article 803037.","journal-title":"Frontiers in Immunology"},{"key":"10298_CR138","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.humpath.2017.06.005","volume":"66","author":"Y Krishna","year":"2017","unstructured":"Krishna, Y., et al. (2017). Inflammatory cell infiltrates in advanced metastatic uveal melanoma. Human Pathology, 66, 159\u2013166.","journal-title":"Human Pathology"},{"issue":"5","key":"10298_CR139","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1038\/s41416-023-02331-w","volume":"129","author":"P Mariani","year":"2023","unstructured":"Mariani, P., et al. (2023). Immunohistochemical characterisation of the immune landscape in primary uveal melanoma and liver metastases. British Journal of Cancer, 129(5), 772\u2013781.","journal-title":"British Journal of Cancer"},{"key":"10298_CR140","doi-asserted-by":"publisher","DOI":"10.3390\/molecules24132450","author":"MC Petralia","year":"2019","unstructured":"Petralia, M. C., et al. (2019). Characterization of the pathophysiological role of CD47 in uveal melanoma. Molecules. https:\/\/doi.org\/10.3390\/molecules24132450","journal-title":"Molecules"},{"key":"10298_CR141","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.3389\/fimmu.2018.01744","volume":"9","author":"Y Lin","year":"2018","unstructured":"Lin, Y., et al. (2018). Notch signaling modulates macrophage polarization and phagocytosis through direct suppression of signal regulatory protein alpha expression. Frontiers in Immunology, 9, 1744.","journal-title":"Frontiers in Immunology"},{"issue":"37","key":"10298_CR142","doi-asserted-by":"publisher","first-page":"60892","DOI":"10.18632\/oncotarget.18492","volume":"8","author":"LE Metayer","year":"2017","unstructured":"Metayer, L. E., et al. (2017). Anti-CD47 antibodies induce phagocytosis of live, malignant B cells by macrophages via the Fc domain, resulting in cell death by phagoptosis. Oncotarget, 8(37), 60892\u201360903.","journal-title":"Oncotarget"},{"key":"10298_CR143","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2026849118","author":"R Upton","year":"2021","unstructured":"Upton, R., et al. (2021). Combining CD47 blockade with trastuzumab eliminates HER2-positive breast cancer cells and overcomes trastuzumab tolerance. Proceedings of the National Academy of Sciences of the United States of America. https:\/\/doi.org\/10.1073\/pnas.2026849118","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10298_CR144","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12020305","author":"J Sun","year":"2020","unstructured":"Sun, J., et al. (2020). Targeting CD47 as a novel immunotherapy for multiple myeloma. Cancers. https:\/\/doi.org\/10.3390\/cancers12020305","journal-title":"Cancers"},{"issue":"10","key":"10298_CR145","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1038\/mt.2013.135","volume":"21","author":"Y Wang","year":"2013","unstructured":"Wang, Y., et al. (2013). Intravenous delivery of siRNA targeting CD47 effectively inhibits melanoma tumor growth and lung metastasis. Molecular Therapy, 21(10), 1919\u20131929.","journal-title":"Molecular Therapy"},{"issue":"21","key":"10298_CR146","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.2217\/fon-2018-0035","volume":"14","author":"B Tong","year":"2018","unstructured":"Tong, B., & Wang, M. (2018). CD47 is a novel potent immunotherapy target in human malignancies: Current studies and future promises. Future Oncology, 14(21), 2179\u20132188.","journal-title":"Future Oncology"},{"issue":"6","key":"10298_CR147","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.blre.2018.04.005","volume":"32","author":"A Russ","year":"2018","unstructured":"Russ, A., et al. (2018). Blocking \u201cdon\u2019t eat me\u201d signal of CD47-SIRPalpha in hematological malignancies, an in-depth review. Blood Reviews, 32(6), 480\u2013489.","journal-title":"Blood Reviews"},{"key":"10298_CR148","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.641240","volume":"12","author":"N Mendez-Sanchez","year":"2021","unstructured":"Mendez-Sanchez, N., et al. (2021). Hepatic dendritic cells in the development and progression of metabolic steatohepatitis. Frontiers in Immunology, 12, Article 641240.","journal-title":"Frontiers in Immunology"},{"issue":"5","key":"10298_CR149","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/j.ajo.2014.07.014","volume":"158","author":"KF Bol","year":"2014","unstructured":"Bol, K. F., et al. (2014). Long overall survival after dendritic cell vaccination in metastatic uveal melanoma patients. American Journal of Ophthalmology, 158(5), 939\u2013947.","journal-title":"American Journal of Ophthalmology"},{"key":"10298_CR150","doi-asserted-by":"publisher","first-page":"785231","DOI":"10.3389\/fimmu.2022.785231","volume":"13","author":"EAT Koch","year":"2022","unstructured":"Koch, E. A. T., et al. (2022). A one-armed Phase I dose escalation trial design: Personalized vaccination with IKKbeta-matured, RNA-loaded dendritic cells for metastatic uveal melanoma. Frontiers in Immunology, 13, 785231.","journal-title":"Frontiers in Immunology"},{"key":"10298_CR151","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.887186","volume":"13","author":"M Sajid","year":"2022","unstructured":"Sajid, M., Liu, L., & Sun, C. (2022). The dynamic role of NK cells in liver cancers: Role in HCC and HBV associated HCC and its therapeutic implications. Frontiers in Immunology, 13, Article 887186.","journal-title":"Frontiers in Immunology"},{"issue":"7534","key":"10298_CR152","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/nature14189","volume":"517","author":"D Artis","year":"2015","unstructured":"Artis, D., & Spits, H. (2015). The biology of innate lymphoid cells. Nature, 517(7534), 293\u2013301.","journal-title":"Nature"},{"issue":"6013","key":"10298_CR153","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1126\/science.1198687","volume":"331","author":"E Vivier","year":"2011","unstructured":"Vivier, E., et al. (2011). Innate or adaptive immunity? The example of natural killer cells. Science, 331(6013), 44\u201349.","journal-title":"Science"},{"key":"10298_CR154","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00719","volume":"10","author":"M Parodi","year":"2019","unstructured":"Parodi, M., et al. (2019). NKp44-NKp44 ligand interactions in the regulation of natural killer cells and other innate lymphoid cells in humans. Frontiers in Immunology, 10, Article 719.","journal-title":"Frontiers in Immunology"},{"key":"10298_CR155","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2015.00495","volume":"6","author":"U Hadad","year":"2015","unstructured":"Hadad, U., et al. (2015). NKp46 clusters at the immune synapse and regulates NK cell polarization. Frontiers in Immunology, 6, Article 495.","journal-title":"Frontiers in Immunology"},{"issue":"10","key":"10298_CR156","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1084\/jem.190.10.1505","volume":"190","author":"D Pende","year":"1999","unstructured":"Pende, D., et al. (1999). Identification and molecular characterization of NKp30, a novel triggering receptor involved in natural cytotoxicity mediated by human natural killer cells. The Journal of Experimental Medicine, 190(10), 1505\u20131516.","journal-title":"The Journal of Experimental Medicine"},{"issue":"10","key":"10298_CR157","doi-asserted-by":"publisher","first-page":"5640","DOI":"10.1073\/pnas.96.10.5640","volume":"96","author":"O Mandelboim","year":"1999","unstructured":"Mandelboim, O., et al. (1999). Human CD16 as a lysis receptor mediating direct natural killer cell cytotoxicity. Proceedings of the National Academy of Sciences of the United States of America, 96(10), 5640\u20135644.","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"3","key":"10298_CR158","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s002510050420","volume":"48","author":"J Glienke","year":"1998","unstructured":"Glienke, J., et al. (1998). The genomic organization of NKG2C, E, F, and D receptor genes in the human natural killer gene complex. Immunogenetics, 48(3), 163\u2013173.","journal-title":"Immunogenetics"},{"issue":"11","key":"10298_CR159","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1182\/blood-2009-08-238469","volume":"115","author":"C Fauriat","year":"2010","unstructured":"Fauriat, C., et al. (2010). Regulation of human NK-cell cytokine and chemokine production by target cell recognition. Blood, 115(11), 2167\u20132176.","journal-title":"Blood"},{"key":"10298_CR160","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.01659","volume":"3","author":"DK Sojka","year":"2014","unstructured":"Sojka, D. K., et al. (2014). Tissue-resident natural killer (NK) cells are cell lineages distinct from thymic and conventional splenic NK cells. eLife, 3, Article e01659.","journal-title":"eLife"},{"issue":"3","key":"10298_CR161","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1084\/jem.20131560","volume":"211","author":"C Daussy","year":"2014","unstructured":"Daussy, C., et al. (2014). T-bet and Eomes instruct the development of two distinct natural killer cell lineages in the liver and in the bone marrow. Journal Of Experimental Medicine, 211(3), 563\u2013577.","journal-title":"Journal Of Experimental Medicine"},{"key":"10298_CR162","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.cytogfr.2018.08.001","volume":"42","author":"B Zitti","year":"2018","unstructured":"Zitti, B., & Bryceson, Y. T. (2018). Natural killer cells in inflammation and autoimmunity. Cytokine & Growth Factor Reviews, 42, 37\u201346.","journal-title":"Cytokine & Growth Factor Reviews"},{"issue":"3","key":"10298_CR163","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1111\/imm.12921","volume":"154","author":"S Kumar","year":"2018","unstructured":"Kumar, S. (2018). Natural killer cell cytotoxicity and its regulation by inhibitory receptors. Immunology, 154(3), 383\u2013393.","journal-title":"Immunology"},{"key":"10298_CR164","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines10121993","author":"JG Fisher","year":"2022","unstructured":"Fisher, J. G., et al. (2022). Disruption of the NKG2A: HLA-E immune checkpoint axis to enhance NK cell activation against cancer. Vaccines. https:\/\/doi.org\/10.3390\/vaccines10121993","journal-title":"Vaccines"},{"issue":"6","key":"10298_CR165","doi-asserted-by":"publisher","first-page":"3590","DOI":"10.4049\/jimmunol.177.6.3590","volume":"177","author":"M Masilamani","year":"2006","unstructured":"Masilamani, M., et al. (2006). CD94\/NKG2A inhibits NK cell activation by disrupting the actin network at the immunological synapse. Journal of Immunology, 177(6), 3590\u20133596.","journal-title":"Journal of Immunology"},{"issue":"18","key":"10298_CR166","doi-asserted-by":"publisher","first-page":"6696","DOI":"10.1073\/pnas.0802736105","volume":"105","author":"BK Kaiser","year":"2008","unstructured":"Kaiser, B. K., et al. (2008). Structural basis for NKG2A\/CD94 recognition of HLA-E. Proceedings of the National Academy of Sciences of the United States of America, 105(18), 6696\u20136701.","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"5","key":"10298_CR167","doi-asserted-by":"publisher","first-page":"2016","DOI":"10.1167\/iovs.02-0810","volume":"44","author":"G Anastassiou","year":"2003","unstructured":"Anastassiou, G., et al. (2003). Expression of classic and nonclassic HLA class I antigens in uveal melanoma. Investigative Ophthalmology & Visual Science, 44(5), 2016\u20132019.","journal-title":"Investigative Ophthalmology & Visual Science"},{"issue":"13","key":"10298_CR168","first-page":"3081","volume":"42","author":"HM Hurks","year":"2001","unstructured":"Hurks, H. M., et al. (2001). Uveal melanoma: No expression of HLA-G. Investigative Ophthalmology & Visual Science, 42(13), 3081\u20133084.","journal-title":"Investigative Ophthalmology & Visual Science"},{"issue":"4","key":"10298_CR169","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1002\/1097-0029(20010215)52:4<396::AID-JEMT1024>3.0.CO;2-V","volume":"52","author":"P Esser","year":"2001","unstructured":"Esser, P., Grisanti, S., & Bartz-Schmidt, K. (2001). TGF-beta in uveal melanoma. Microscopy Research and Technique, 52(4), 396\u2013400.","journal-title":"Microscopy Research and Technique"},{"issue":"2","key":"10298_CR170","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1167\/iovs.10-5979","volume":"52","author":"IH Bronkhorst","year":"2011","unstructured":"Bronkhorst, I. H., et al. (2011). Detection of M2-macrophages in uveal melanoma and relation with survival. Investigative Ophthalmology & Visual Science, 52(2), 643\u2013650.","journal-title":"Investigative Ophthalmology & Visual Science"},{"issue":"11","key":"10298_CR171","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1136\/bjo.81.11.989","volume":"81","author":"DJ Blom","year":"1997","unstructured":"Blom, D. J., et al. (1997). HLA expression in a primary uveal melanoma, its cell line, and four of its metastases. British Journal of Ophthalmology, 81(11), 989\u2013993.","journal-title":"British Journal of Ophthalmology"},{"issue":"9","key":"10298_CR172","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1158\/1078-0432.CCR-15-2294","volume":"22","author":"LD Rothermel","year":"2016","unstructured":"Rothermel, L. D., et al. (2016). Identification of an immunogenic subset of metastatic uveal melanoma. Clinical Cancer Research, 22(9), 2237\u20132249.","journal-title":"Clinical Cancer Research"},{"key":"10298_CR173","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.767175","volume":"12","author":"RF Kraus","year":"2021","unstructured":"Kraus, R. F., & Gruber, M. A. (2021). Neutrophils-from bone marrow to first-line defense of the innate immune system. Frontiers in Immunology, 12, Article 767175.","journal-title":"Frontiers in Immunology"},{"key":"10298_CR174","doi-asserted-by":"publisher","DOI":"10.1038\/s41421-020-0157-z","volume":"6","author":"J Zhao","year":"2020","unstructured":"Zhao, J., et al. (2020). Single-cell RNA sequencing reveals the heterogeneity of liver-resident immune cells in human. Cell Discovery, 6, Article 22.","journal-title":"Cell Discovery"},{"issue":"10","key":"10298_CR175","doi-asserted-by":"publisher","first-page":"5226","DOI":"10.4049\/jimmunol.1202909","volume":"190","author":"A Wehr","year":"2013","unstructured":"Wehr, A., et al. (2013). Chemokine receptor CXCR6-dependent hepatic NK T cell accumulation promotes inflammation and liver fibrosis. Journal of Immunology, 190(10), 5226\u20135236.","journal-title":"Journal of Immunology"},{"issue":"5663","key":"10298_CR176","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1126\/science.1092385","volume":"303","author":"V Brinkmann","year":"2004","unstructured":"Brinkmann, V., et al. (2004). Neutrophil extracellular traps kill bacteria. Science, 303(5663), 1532\u20131535.","journal-title":"Science"},{"issue":"1","key":"10298_CR177","doi-asserted-by":"publisher","first-page":"144","DOI":"10.2353\/ajpath.2008.080081","volume":"173","author":"M Lin","year":"2008","unstructured":"Lin, M., et al. (2008). Matrix metalloproteinase-8 facilitates neutrophil migration through the corneal stromal matrix by collagen degradation and production of the chemotactic peptide pro-Gly-Pro. American Journal of Pathology, 173(1), 144\u2013153.","journal-title":"American Journal of Pathology"},{"issue":"6\u20137","key":"10298_CR178","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1016\/j.biocel.2007.11.008","volume":"40","author":"CT Pham","year":"2008","unstructured":"Pham, C. T. (2008). Neutrophil serine proteases fine-tune the inflammatory response. International Journal of Biochemistry & Cell Biology, 40(6\u20137), 1317\u20131333.","journal-title":"International Journal of Biochemistry & Cell Biology"},{"key":"10298_CR179","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14235789","author":"JJ Waninger","year":"2022","unstructured":"Waninger, J. J., et al. (2022). Prognostic hematologic biomarkers following immune checkpoint inhibition in metastatic uveal melanoma. Cancers. https:\/\/doi.org\/10.3390\/cancers14235789","journal-title":"Cancers"},{"issue":"1","key":"10298_CR180","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-020-0158-0","volume":"6","author":"MJ Jager","year":"2020","unstructured":"Jager, M. J., et al. (2020). Uveal melanoma. Nature Reviews. Disease Primers, 6(1), Article 24.","journal-title":"Nature Reviews. Disease Primers"},{"issue":"8","key":"10298_CR181","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1158\/2159-8290.CD-19-1220","volume":"10","author":"M Carbone","year":"2020","unstructured":"Carbone, M., et al. (2020). Biological mechanisms and clinical significance of BAP1 mutations in human cancer. Cancer Discovery, 10(8), 1103\u20131120.","journal-title":"Cancer Discovery"},{"issue":"3","key":"10298_CR182","doi-asserted-by":"publisher","DOI":"10.1111\/pcmr.70021","volume":"38","author":"CJ Cunanan","year":"2025","unstructured":"Cunanan, C. J., et al. (2025). BAP1 loss affords lipotoxicity resistance in uveal melanoma. Pigment Cell & Melanoma Research, 38(3), Article e70021.","journal-title":"Pigment Cell & Melanoma Research"},{"issue":"3","key":"10298_CR183","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/s41418-017-0012-4","volume":"25","author":"L Galluzzi","year":"2018","unstructured":"Galluzzi, L., et al. (2018). Molecular mechanisms of cell death: Recommendations of the Nomenclature Committee on Cell Death 2018. Cell Death & Differentiation, 25(3), 486\u2013541.","journal-title":"Cell Death & Differentiation"},{"issue":"8","key":"10298_CR184","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0105372","volume":"9","author":"L Asnaghi","year":"2014","unstructured":"Asnaghi, L., et al. (2014). Hypoxia promotes uveal melanoma invasion through enhanced Notch and MAPK activation. PLoS One, 9(8), Article e105372.","journal-title":"PLoS One"},{"issue":"7","key":"10298_CR185","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1158\/1078-0432.CCR-18-1368","volume":"25","author":"L Dong","year":"2019","unstructured":"Dong, L., et al. (2019). Arylsulfonamide 64B inhibits hypoxia\/HIF-induced expression of c-Met and CXCR4 and reduces primary tumor growth and metastasis of uveal melanoma. Clinical Cancer Research, 25(7), 2206\u20132218.","journal-title":"Clinical Cancer Research"},{"issue":"1","key":"10298_CR186","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1080\/15548627.2024.2395142","volume":"21","author":"J Sun","year":"2025","unstructured":"Sun, J., et al. (2025). Hypoxia-induced BNIP3 facilitates the progression and metastasis of uveal melanoma by driving metabolic reprogramming. Autophagy, 21(1), 191\u2013209.","journal-title":"Autophagy"},{"issue":"13","key":"10298_CR187","doi-asserted-by":"publisher","first-page":"14062","DOI":"10.1002\/cam4.6058","volume":"12","author":"LP Del Carpio","year":"2023","unstructured":"Del Carpio, L. P., et al. (2023). Differences in glucose metabolic activity in liver metastasis separates two groups of metastatic uveal melanoma patients with different prognosis. Cancer Medicine, 12(13), 14062\u201314071.","journal-title":"Cancer Medicine"},{"issue":"11","key":"10298_CR188","doi-asserted-by":"publisher","first-page":"1846","DOI":"10.1038\/s41416-024-02866-6","volume":"131","author":"C Chattopadhyay","year":"2024","unstructured":"Chattopadhyay, C., et al. (2024). Imipridones inhibit tumor growth and improve survival in an orthotopic liver metastasis mouse model of human uveal melanoma. British Journal of Cancer, 131(11), 1846\u20131857.","journal-title":"British Journal of Cancer"},{"issue":"840","key":"10298_CR189","doi-asserted-by":"publisher","first-page":"eadn8376","DOI":"10.1126\/scisignal.adn8376","volume":"17","author":"V Chua","year":"2024","unstructured":"Chua, V., et al. (2024). Slow proliferation of BAP1-deficient uveal melanoma cells is associated with reduced S6 signaling and resistance to nutrient stress. Science Signaling, 17(840), eadn8376.","journal-title":"Science Signaling"},{"key":"10298_CR190","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12102950","author":"K Slater","year":"2020","unstructured":"Slater, K., et al. (2020). High cysteinyl leukotriene receptor 1 expression correlates with poor survival of uveal melanoma patients and cognate antagonist drugs modulate the growth, cancer secretome, and metabolism of uveal melanoma cells. Cancers. https:\/\/doi.org\/10.3390\/cancers12102950","journal-title":"Cancers"},{"key":"10298_CR191","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-016-2411-1","volume":"16","author":"M Yang","year":"2016","unstructured":"Yang, M., et al. (2016). Macrophage phenotypic subtypes diametrically regulate epithelial-mesenchymal plasticity in breast cancer cells. Bmc Cancer, 16, Article 419.","journal-title":"Bmc Cancer"},{"issue":"1","key":"10298_CR192","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-022-03667-2","volume":"20","author":"Y He","year":"2022","unstructured":"He, Y., et al. (2022). Multi-perspective comparison of the immune microenvironment of primary colorectal cancer and liver metastases. Journal of Translational Medicine, 20(1), Article 454.","journal-title":"Journal of Translational Medicine"},{"issue":"5","key":"10298_CR193","doi-asserted-by":"publisher","first-page":"520","DOI":"10.7150\/ijbs.8879","volume":"10","author":"YC Liu","year":"2014","unstructured":"Liu, Y. C., et al. (2014). Macrophage polarization in inflammatory diseases. International Journal of Biological Sciences, 10(5), 520\u2013529.","journal-title":"International Journal of Biological Sciences"},{"key":"10298_CR194","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00946","volume":"10","author":"J Mikulak","year":"2019","unstructured":"Mikulak, J., et al. (2019). Hepatic natural killer cells: Organ-specific sentinels of liver immune homeostasis and physiopathology. Frontiers in Immunology, 10, Article 946.","journal-title":"Frontiers in Immunology"},{"key":"10298_CR195","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.coi.2016.11.003","volume":"44","author":"VC Lam","year":"2017","unstructured":"Lam, V. C., & Lanier, L. L. (2017). NK cells in host responses to viral infections. Current Opinion in Immunology, 44, 43\u201351.","journal-title":"Current Opinion in Immunology"},{"key":"10298_CR196","doi-asserted-by":"publisher","first-page":"175883592311601","DOI":"10.1177\/17588359231160140","volume":"15","author":"S Howlett","year":"2023","unstructured":"Howlett, S., et al. (2023). Tebentafusp: A first-in-class treatment for metastatic uveal melanoma. Therapeutic Advances in Medical Oncology, 15, 17588359231160140.","journal-title":"Therapeutic Advances in Medical Oncology"},{"issue":"4","key":"10298_CR197","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.4049\/jimmunol.1401894","volume":"194","author":"X Lu","year":"2015","unstructured":"Lu, X., et al. (2015). Alkylating agent melphalan augments the efficacy of adoptive immunotherapy using tumor-specific CD4+ T cells. The Journal of Immunology, 194(4), 2011\u20132021.","journal-title":"The Journal of Immunology"},{"issue":"8","key":"10298_CR198","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1158\/0008-5472.CAN-14-2089","volume":"75","author":"AM Dudek-Peric","year":"2015","unstructured":"Dudek-Peric, A. M., et al. (2015). Antitumor immunity triggered by melphalan is potentiated by melanoma cell surface-associated calreticulin. Cancer Research, 75(8), 1603\u20131614.","journal-title":"Cancer Research"}],"container-title":["Cancer and Metastasis Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10555-025-10298-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10555-025-10298-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10555-025-10298-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T16:04:42Z","timestamp":1761753882000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10555-025-10298-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,29]]},"references-count":198,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["10298"],"URL":"https:\/\/doi.org\/10.1007\/s10555-025-10298-8","relation":{},"ISSN":["1573-7233"],"issn-type":[{"value":"1573-7233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,29]]},"assertion":[{"value":"28 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"N\/A.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}],"article-number":"80"}}